The Revised International Staging System (R-ISS)

FAQ Library published on April 7, 2016
Download Transcript Download Audio
Paul G. Richardson, MD
R.J. Corman Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Welcome to Managing Myeloma. My name is Dr. Paul Richardson and I am the clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston, Massachusetts. It is my pleasure to be with you today to discuss the so-called R-ISS, which is basically a Revised International Staging System designed to further assess risk. Now it is designed to improve our prognostication of newly diagnosed multiple myeloma patients and it does tell us some important new information. The most important is that it incorporates the impact of high-risk cytogenetics and at the same time LDH. And so what it means is that the traditional ISS stage I patient remains ISS stage I, as long as they have a normal LDH and they are without adverse cytogenetics, which in this case include del(17p), t(4;14) and t(14;16). Now in contrast, the stage III patients combine both ISS Stage III criteria with an elevated LDH and any of the three adverse cytogenetic findings, namely del(17p), t(4;14) or t(14;16). And ISS Stage II-R, as it is now called, is basically anything in between. I think why this is very useful is because it combines the importance of the ISS staging as classically defined, which I do think in my own practice is important, but at the same time it gives us a rational structure around how to incorporate the impact of the high LDH, which we know is an adverse feature as well as the most important FISH-based adverse cytogenetics.

Thank you for viewing this activity. For additional resources, please view the other educational activities on ManagingMyeloma.com.

Reviewed on January 17, 2017 for clinical relevance.

Last modified: February 8, 2017
Related Items by Author
The what, how, and when of CAR-T therapy in multiple myeloma
Paul G. Richardson, MD
FAQ Library published on October 24, 2018
What are the available options for patients relapsing beyond the third line of therapy?
Paul G. Richardson, MD
FAQ Library published on October 10, 2018
Where isatuximab may fit in the treatment paradigm for relapsed/refractory multiple myeloma
Paul G. Richardson, MD
FAQ Library published on February 23, 2018
What are truly myeloma defining events, and how will their assessment impact on clinical practice?
Paul G. Richardson, MD
FAQ Library published on May 5, 2016
How can we effectively address medication compliance and adherence in the outpatient setting to oral medicines that we use in myeloma?
Paul G. Richardson, MD
FAQ Library published on April 18, 2016
What is the role of consolidation therapy in multiple myeloma and is there a best approach?
Paul G. Richardson, MD
FAQ Library published on September 4, 2013
What are some interventions for asthenia?
Paul G. Richardson, MD
FAQ Library published on May 13, 2011 in Comorbidities/SEs, Patient Communication
How do we manage pain in myeloma patients?
Paul G. Richardson, MD
FAQ Library published on October 12, 2009 in Comorbidities/SEs
How do I manage bone disease in my myeloma patients?
Paul G. Richardson, MD
FAQ Library published on October 12, 2009 in Comorbidities/SEs, Bone Disease